Abstract
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody testing, surrogate neutralization assays, and T cell assays. Patients were immunized with two doses of vaccine and immunogenicity assessed after each dose using the above tests. CD4+ and CD8+ T cell responses were assessed in a subset using flow-cytometry. A total of 127 patients were enrolled of which 110 provided serum at all time points. A positive anti-RBD antibody was seen in 5.0% after one dose and 34.5% after two doses. Neutralizing antibody was present in 26.9%. Of note, 28.5% of patients with anti-RBD did not have neutralizing antibody. T cell responses in a sub-cohort of 48 patients showed a positive CD4+ T cell response in 47.9%. Of note, in this sub-cohort, 46.2% of patients with a negative anti-RBD, still had a positive CD4+ T cell response. The vaccine was safe and well-tolerated. In summary, immunogenicity of mRNA-1273 COVID-19 vaccine was modest, but a subset of patients still develop neutralizing antibody and CD4+T- cell responses. Importantly polyfunctional CD4+T cell responses were observed in a significant portion who were antibody negative, further highlighting the importance of vaccination in this patient population. IRB Statement: This study was approved by the University Health Network Research Ethics Board (CAPCR ID 20-6069).
Keywords: clinical research/practice; infection and infectious agents – viral; infectious disease; vaccine.
【저자키워드】 Vaccine, Infectious disease, clinical research/practice, infection and infectious agents - viral, 【초록키워드】 COVID-19, neutralizing antibody, Vaccine, Antibody testing, vaccination, antibody, Infection, Ethics, Organ transplant, serum, response, Patient, network, university, T cell response, CD8+ T cell, CD4+ T cell, Combination, dose, severe disease, anti-RBD, Safe, high risk, mRNA-1273 COVID-19 vaccine, infectious agent, mRNA-1273 vaccine, CD4+, doses, positive, recipient, neutralization assays, patient population, board, T cell assays, flow-cytometry, responses, IRB, Cell, immunized, enrolled, develop, approved, provided, subset, highlighting, Solid, sub-cohort, were assessed, 【제목키워드】 SARS-CoV-2, Cellular immune response, solid organ transplant, mRNA-1273 vaccine, recipient,